CHMP Adopts Positive Opinion for Full Marketing Authorization of Gilead’s Hepcludex® Treatment of HDV 

Gilead Sciences CHMP Adopted Positive Opinion for Hepcludex®
Today, May 4, 2023, Gilead Sciences (GILD) acknowledged that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for adults having chronic HDV and compensated liver disease,  recommended granting full Marketing Authorization (MA) that . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.